Cas:4427-56-9 4-methyl-2-propan-2-ylphenol manufacturer & supplier

Chemical Name:4-methyl-2-propan-2-ylphenol

CAS.NO:4427-56-9

Synonyms:m-Cymen-4-ol;EINECS 224-611-9;4-hydroxy-m-cymene;Phenol,2-isopropyl-4-methyl;1-Hydroxy-4-methyl-2-isopropylbenzene;2-Isopropyl-4-methylphenol;4-Methyl-2-isopropylphenol;2-Isopropyl-p-cresol;p-Cresol,2-isopropyl

Molecular Formula:C₁₀H₁₄O

Molecular Weight:150.21800

HS Code:2907199090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:237.2ºC at 760 mmHg

Density:0.974 g/cm3

Index of Refraction:1.523

PSA:20.23000

Exact Mass:150.10400

LogP:2.82400

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like m-Cymen-4-ol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,p-Cresol,2-isopropyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,m-Cymen-4-ol Use and application,1-Hydroxy-4-methyl-2-isopropylbenzene technical grade,usp/ep/jp grade.

Related News: The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 4-methyl-2-propan-2-ylphenol manufacturer The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 4-methyl-2-propan-2-ylphenol supplier AXON is planning a follow-up trial that will include a better-defined group of Alzheimer’s patients suffering from both amyloid plaques and tau tangles, Novak said. 4-methyl-2-propan-2-ylphenol vendor The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 4-methyl-2-propan-2-ylphenol factory The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful.